Amplify Weight Loss Drug & Treatment ETFNYSE Arca:THNR
- LAST PRICE23.15
- TODAY'S CHANGE (%)-0.80 (-3.32%)
- Bid / Lots---/ ---
- Ask / Lots24.31/ 1
- Open / Previous Close23.48 / 23.94
- Day Range
- 52 Week Range
- Volume3,090
- Overall Morningstar RatingNot Ratedout of 268 funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | THNR |
|---|---|---|
| 09:39 ET | 145 | 23.4818 |
| 10:06 ET | 850 | 23.32 |
| 10:56 ET | 357 | 23.2301 |
| 11:03 ET | 200 | 23.14 |
| 12:19 ET | 600 | 23.2857 |
| 02:00 ET | 163 | 23.3 |
| 03:35 ET | 177 | 23.11 |
| 04:00 ET | 177 | 23.1493 |
Daily Premium/Discount
| Date | Daily Premium/Discount |
|---|---|
| 08/20/2024 | -0.20% |
| 08/21/2024 | 0.21% |
| 08/22/2024 | -0.03% |
| 08/23/2024 | 0.25% |
| 08/26/2024 | 0.04% |
| 08/27/2024 | 0.26% |
| 08/28/2024 | 0.06% |
| 08/29/2024 | 0.11% |
| 08/30/2024 | 0.13% |
| 09/03/2024 | 0.16% |
| 09/04/2024 | 0.03% |
| 09/05/2024 | 0.22% |
| 09/09/2024 | 0.06% |
| 09/10/2024 | 0.12% |
| 09/11/2024 | 0.05% |
| 09/12/2024 | 0.24% |
| 09/13/2024 | 0.23% |
| 09/16/2024 | 0.23% |
| 09/17/2024 | 0.18% |
| 09/18/2024 | 0.12% |
| 09/19/2024 | 0.50% |
| 09/20/2024 | 0.50% |
| 09/23/2024 | 0.51% |
| 09/24/2024 | 0.33% |
| 09/25/2024 | 0.37% |
| 09/26/2024 Largest Premium | 0.52% |
| 09/27/2024 Largest Discount | -0.26% |
| 09/30/2024 | 0.21% |
| 10/01/2024 | 0.13% |
| 10/02/2024 | 0.46% |
| 10/03/2024 | 0.26% |
| 10/04/2024 | 0.51% |
| 10/07/2024 | 0.11% |
| 10/08/2024 | 0.46% |
| 10/09/2024 | 0.22% |
| 10/10/2024 | 0.34% |
| 10/11/2024 | 0.36% |
| 10/14/2024 | 0.22% |
| 10/15/2024 | 0.01% |
| 10/16/2024 | 0.40% |
| 10/17/2024 | 0.31% |
| 10/18/2024 | 0.38% |
| 10/21/2024 | 0.19% |
| 10/22/2024 | 0.26% |
| 10/23/2024 | 0.12% |
| 10/24/2024 | 0.23% |
| 10/25/2024 | 0.14% |
| 10/28/2024 | 0.30% |
| 10/30/2024 | 0.00% |
| 10/31/2024 | 0.21% |
| 11/01/2024 | 0.28% |
| 11/04/2024 | 0.23% |
| 11/05/2024 | 0.35% |
| 11/06/2024 | 0.25% |
| 11/08/2024 | -0.17% |
| 11/11/2024 | 0.08% |
| 11/12/2024 | 0.07% |
| 11/13/2024 | 0.20% |
| 11/14/2024 | -0.17% |
| 11/15/2024 | 0.05% |
| Non-US Stock | 51.9% |
|---|---|
| US Stock | 47.5% |
| Cash | 0.7% |
| Convertible | 0 |
| Non-US Bond | 0 |
| Other | 0 |
| Healthcare | 90.8% |
|---|---|
| Industrials | 4.8% |
| Basic Mat. | 3.2% |
| Consumer Defensive | 0.6% |
| Communication Services | 0 |
| Consumer Cyclical | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Real Estate | 0 |
| Technology | 0 |
| Utilities | 0 |
| United States | 47.8% |
|---|---|
| Asia/Oceania | 17.3% |
| Europe | 4.5% |
| Africa | 0 |
| Latin America | 0 |
| Canada | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
Eli Lilly and Co | Long | 14.5% | 0.00% | $657.2K |
Novo Nordisk AS ADR | Long | 13.4% | 0.00% | $606.7K |
Roche Holding AG | Long | 5.5% | 0.00% | $248.2K |
Pfizer Inc | Long | 5.3% | 0.00% | $239.6K |
Amgen Inc | Long | 5.3% | 0.00% | $239.5K |
Chugai Pharmaceutical Co Ltd | Long | 5.2% | 0.00% | $236.1K |
AstraZeneca PLC ADR | Long | 4.9% | 0.00% | $222.4K |
Thermo Fisher Scientific Inc | Long | 4.8% | 0.00% | $219.6K |
Merck & Co Inc | Long | 4.8% | 0.00% | $219.3K |
FUJIFILM Holdings Corp | Long | 4.8% | 0.00% | $217.4K |
Reports
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | Not Rated |
| 3 Year Rating | Not Rated |
| 5 Year Rating | Not Rated |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | VettaFi Weight Loss Drug & Treat TR USD |
|---|---|
Category | |
Sponsor | Amplify Investments LLC |
Inception | May 20, 2024 |
The investment seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.
| Total Net Assets | $4.5M |
|---|---|
| Shares Out. | 180.0K |
| Net Asset Value (NAV) | $23.14 |
| Prem/Discount to NAV | 0.05% |
| P/E Ratio | 32.6 |
| Dividend Yield | --- |
| Dividend per Share | --- |
| Ex-Dividend Date | --- |
| Dividend Payment Date | --- |
| Beta | --- |
| Morningstar Investment Style | Health |
| Equity Style | Large Cap Growth |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.59% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | --- |